Biota Pharmaceuticals Inc (BOTA) 5.47 $BOTA
Global Bacterial Pneumonia Therapeutic Pipeline Review 2014 - Analysis of 6 Companies and 6 Drug Profiles
M2 - Tue Apr 15, 6:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jxbl8g/bacterial) has announced the addition of the "Bacterial Pneumonia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bacterial Pneumonia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bacterial Pneumonia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Bacterial Pneumonia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Bacterial Pneumonia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Bacterial Pneumonia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Bacterial Pneumonia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Bacterial Pneumonia - Companies Involved in Therapeutics Development - Paratek Pharmaceuticals, Inc. - Bayer AG - ImmuVen, Inc. - Biota Pharmaceuticals, Inc. - Humabs BioMed SA - Dong-A Socio Holdings Co Ltd Drug Profiles - amikacin - tedizolid phosphate - omadacycline tosylate - Gyrase Program - IMV-0123 - MAb Against S aureus For more information visit http://www.researchandmarkets.com/research/jxbl8g/bacterial
Biota Pharmaceuticals, Inc. to Present at the 26th Annual ROTH Conference
GlobeNewswire - Mon Feb 24, 3:50PM CST
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) today announced that its President and Chief Executive Officer, Russell H. Plumb, will present an update on the company at the 26th Annual ROTH Conference at 12:30 p.m. PDT, March 11, 2014, at The Ritz-Carlton, Dana Point in California.
Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics
M2 - Tue Feb 18, 2:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/kkvg3x/competitor) has announced the addition of the "Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics" report to their offering. Clostridium difficile infections (CDI) are a major public health concern. CDI are becoming increasingly prevalent in hospitals, long-term and primary-care facilities, primarily in patients whose normal intestinal flora have been compromised by antibiotic treatment. CDI primary virulence mechanismis the production of two toxins, TcdA and TcdB, which glucosylate Rho-family GTPases, disrupt the actin cytoskeleton, and causing cytotoxicity and inflammation. The present Competitive Intelligence Report about prophylaxis and therapy of Clostridium difficile infections provides a competitor evaluation in the field of new molecules or microorganisms for prevention or treatment of Clostridium difficle infections as of January 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently active projects in research and development of antibodies, proteins, peptides, vaccines, microorganisms and small molecules for prevention and treatment of Clostridium difficile infections. In addition, the report lists company-specific R&D pipelines of C. difficile vaccines and therapeutics. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Key Topics Covered - C. difficile Vaccines - C. difficile Antibodies - C. difficile Antibiotics - C. difficile targeting Microorganisms - C. difficile Anti-Infectives - Corporate C. difficile Vaccines & Therapeutics R&D Pipelines Companies Mentioned - Actelion - AIMM Therapeutics - AmpliPhi Biosciences - Astellas Pharma - AstraZeneca (MedImmune) - Aviex Technologies - Biota Pharmaceuticals - Crestone - Cubist Pharmaceuticals - DaVolterra - Immuron - Merck - Novacta Therapeutics - Novartis - Pfizer - Prokarium - Rebiotix - Sanofi Pasteur - Seres Health - Shire (ViroPharma) - Stellar Biotechnologies - Summit - Synthetic Biologics - Valneva - VaxInnate - Venenum Biodesign For more information visit http://www.researchandmarkets.com/research/kkvg3x/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Biota Pharmaceuticals Reports Second Quarter 2013 Financial Results and Recent Corporate Developments
GlobeNewswire - Mon Feb 10, 6:00AM CST
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company"
today announced its financial results for the three month and six month periods ended December 31, 2013, and provided an update on recent corporate developments.
Biota Pharmaceuticals to Host Conference Call to Report Second Quarter Financial Results on February 10, 2014
GlobeNewswire - Mon Feb 03, 8:00AM CST
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company" announced today that management will host a conference call on Monday, February 10, 2014 at 9:00a.m EST to review the Company's second quarter financial results and provide an update on recent corporate developments. The Company will issue a press release summarizing its financial results on the same day, prior to the conference call.
Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 03, 2:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/fg3mhf/hospital_acquired) has announced the addition of the "Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2013" report to their offering. 'Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hospital Acquired Pneumonia (HAP), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hospital Acquired Pneumonia (HAP). Scope - A snapshot of the global therapeutic scenario for Hospital Acquired Pneumonia (HAP). - A review of the Hospital Acquired Pneumonia (HAP) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hospital Acquired Pneumonia (HAP) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned AstraZeneca PLC Cubist Pharmaceuticals, Inc. Basilea Pharmaceutica AG Aridis Pharmaceuticals LLC Tetraphase Pharmaceuticals Inc. Meiji Seika Pharma Co., Ltd. Biota Pharmaceuticals, Inc. Adenium Biotech ApS Melinta Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/fg...l_acquired About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Enterococcus Faecium Infections - Pipeline Review, H2 2013 Research Report
M2 - Wed Jan 29, 2:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/zdqfb5/enterococcus) has announced the addition of the "Enterococcus Faecium Infections - Pipeline Review, H2 2013" report to their offering. 'Enterococcus Faecium Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Enterococcus Faecium Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Enterococcus Faecium Infections. Scope - A snapshot of the global therapeutic scenario for Enterococcus Faecium Infections. - A review of the Enterococcus Faecium Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Enterococcus Faecium Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Dainippon Sumitomo Pharma Co., Ltd. Aquapharm Biodiscovery Limited Cellceutix Corporation Omnia Molecular Ltd. Biota Pharmaceuticals, Inc. Abgentis Limited Melinta Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/zd...terococcus About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Biota Announces Full Exercise of Over-Allotment Option
GlobeNewswire - Tue Jan 14, 6:00AM CST
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company" today announced that Guggenheim Securities, LLC has exercised its option to purchase an additional 872,085 common shares to cover over-allotments in connection with the Company's public offering of its common shares. The full exercise of the over-allotment option increases the net proceeds to the company, after underwriting discounts and commissions and estimated offering expenses, from approximately $23.3 million to approximately $26.9 million. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.
Biota Prices $25 Million Public Offering
GlobeNewswire - Fri Jan 10, 7:30AM CST
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company" today announced that it has priced a public offering of 5,813,900 shares of its common stock at a purchase price of $4.30 per share for an aggregate offering amount of approximately $25 million. The net proceeds to Biota from the sale of the shares, after underwriting discounts and commissions and other offering expenses, are expected to be approximately $23.3 million. Biota has granted the underwriters a 30-day option to purchase up to 872,085 additional shares to cover over-allotments, if any. The offering is expected to close on January 15, 2014, subject to customary closing conditions. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.
Biota Pharmaceuticals Inc proposes public offering of common shares
M2 - Fri Jan 10, 4:47AM CST
Biopharmaceutical company Biota Pharmaceuticals Inc (NasdaqGS:BOTA) said on Thursday that it plans to start a public offering of its common stock.
Biota Announces Proposed Public Offering
GlobeNewswire - Thu Jan 09, 3:01PM CST
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company" today announced its intention, subject to market and other conditions, to commence a public offering of its common stock. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.
Biota Pharmaceuticals Inc announces approval of Laninamivir Octanoate in Japan for the prevention of influenza
M2 - Mon Dec 23, 6:33AM CST
Biopharmaceutical company Biota Pharmaceuticals Inc (NasdaqGS:BOTA) revealed on Friday the receipt of regulatory approval in Japan to manufacture and market Inavir Dry Powder Inhaler 20mg for the prevention of influenza A and B.
Biota Reports That Laninamivir Octanoate is Approved for the Prevention of Influenza in Japan
GlobeNewswire - Fri Dec 20, 3:49PM CST
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company" today reported that Daiichi Sankyo Company, Limited ("Daiichi Sankyo" has been granted regulatory approval in Japan to manufacture and market Inavir Dry Powder Inhaler 20mg (generic name laninamivir octanoate) for the prevention of influenza A and B. Inavir was successfully developed and launched by Daiichi Sankyo in Japan for treatment of influenza A and B viruses in October, 2010. Biota is developing laninamivir octanoate outside of Japan for the treatment of influenza, and is currently conducting a large, multi-national Phase 2 trial of laninamivir octanoate in adults infected with influenza. In 2003, the Company and Daiichi Sankyo entered into a collaboration and license agreement to develop long-acting neuraminidase inhibitors, including laninamivir octanoate, and in March 2009, the parties entered into a commercialization agreement, pursuant to which Daiichi Sankyo obtained exclusive marketing rights to laninamivir octanoate in Japan.
Biota reports launch of Phase 2 IGLOO trial of LANI in the Northern Hemisphere for treating influenza
M2 - Thu Dec 05, 10:27AM CST
Biopharmaceutical company Biota Pharmaceuticals Inc (NasdaqGS:BOTA) reported on Thursday the start of dosing of patients under its ongoing Phase 2, randomised, double blind, placebo controlled, parallel arm clinical trial of laninamivir octanoate (LANI) in the Northern Hemisphere.
Biota Initiates Dosing in Phase 2 IGLOO Trial of LANI in the Northern Hemisphere
GlobeNewswire - Thu Dec 05, 7:03AM CST
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company" today announced that it has commenced dosing patients in the Northern Hemisphere portion of its ongoing Phase 2, randomized, double blind, placebo controlled, parallel arm clinical trial of laninamivir octanoate (LANI). The trial, referred to as "IGLOO", compares the safety and efficacy of 40 mg and 80 mg of LANI with placebo, all delivered by a TwinCaps inhaler in adults with presumed influenza A or B infection. The trial was initiated in the Southern Hemisphere in June and is now continuing in multiple countries in the Northern Hemisphere. The Company's goal is to complete enrollment in the IGLOO trial by the end of the influenza season in the Northern Hemisphere and have top-line data available in mid-2014. IGLOO is being conducted in connection with the Company's contract with the U.S. Office of Biomedical Advanced Research and Development Authority ("BARDA" . Further details regarding the design of IGLOO are available at www.clinicaltrials.gov.
Biota Initiates Additional Clinical Trials of Laninamivir Octanoate
GlobeNewswire - Tue Nov 19, 6:00AM CST
Biota Pharmaceuticals Inc. ("Biota" (Nasdaq:BOTA) announced today that it has commenced dosing in two Phase 1 clinical trials of laninamivir octanoate ("LANI" , its long-acting neuraminidase inhibitor being developed for the treatment of influenza.
Novartis Reports Positive Results for Avian Flu Vaccine
Leo Sun, The Motley Fool - Motley Fool - Thu Nov 14, 2:18PM CST
Novartis today announced positive clinical trial results for its vaccine for the H7N9 avian flu, marking the first major step made by a large pharmaceutical company in treating the virus. There have been 135 confirmed H7N9 cases of and...
Biota Pharmaceuticals Reports First Quarter Financial Results
GlobeNewswire - Thu Nov 07, 6:00AM CST
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company" today announced its financial results for the three month period ended September 30, 2013.
Biota Pharmaceuticals to Host Conference Call to Report First Quarter Financial Results on November 7, 2013
GlobeNewswire - Mon Oct 28, 8:00AM CDT
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company" announced today that management will host a conference call on Thursday, November 7, 2013 at 9:00a.m. EST to review the Company's first quarter financial results and provide an update on recent corporate developments. The Company will issue a press release summarizing its financial results on the same day, prior to the conference call.
Biota Pharmaceuticals Reports Fourth Quarter and Fiscal Year-End Financial Results
GlobeNewswire - Wed Sep 18, 6:00AM CDT
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company" today announced financial results for its fourth quarter and fiscal year ended June 30, 2013, and provided an update on recent corporate developments and its financial guidance.
Global Bacterial Pneumonia Therapeutic Pipeline Review 2014 - Analysis of 6 Companies and 6 Drug Profiles
M2 - Tue Apr 15, 6:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jxbl8g/bacterial) has announced the addition of the "Bacterial Pneumonia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bacterial Pneumonia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bacterial Pneumonia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Bacterial Pneumonia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Bacterial Pneumonia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Bacterial Pneumonia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Bacterial Pneumonia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Bacterial Pneumonia - Companies Involved in Therapeutics Development - Paratek Pharmaceuticals, Inc. - Bayer AG - ImmuVen, Inc. - Biota Pharmaceuticals, Inc. - Humabs BioMed SA - Dong-A Socio Holdings Co Ltd Drug Profiles - amikacin - tedizolid phosphate - omadacycline tosylate - Gyrase Program - IMV-0123 - MAb Against S aureus For more information visit http://www.researchandmarkets.com/research/jxbl8g/bacterial
Biota Pharmaceuticals, Inc. to Present at the 26th Annual ROTH Conference
GlobeNewswire - Mon Feb 24, 3:50PM CST
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) today announced that its President and Chief Executive Officer, Russell H. Plumb, will present an update on the company at the 26th Annual ROTH Conference at 12:30 p.m. PDT, March 11, 2014, at The Ritz-Carlton, Dana Point in California.
Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics
M2 - Tue Feb 18, 2:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/kkvg3x/competitor) has announced the addition of the "Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics" report to their offering. Clostridium difficile infections (CDI) are a major public health concern. CDI are becoming increasingly prevalent in hospitals, long-term and primary-care facilities, primarily in patients whose normal intestinal flora have been compromised by antibiotic treatment. CDI primary virulence mechanismis the production of two toxins, TcdA and TcdB, which glucosylate Rho-family GTPases, disrupt the actin cytoskeleton, and causing cytotoxicity and inflammation. The present Competitive Intelligence Report about prophylaxis and therapy of Clostridium difficile infections provides a competitor evaluation in the field of new molecules or microorganisms for prevention or treatment of Clostridium difficle infections as of January 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently active projects in research and development of antibodies, proteins, peptides, vaccines, microorganisms and small molecules for prevention and treatment of Clostridium difficile infections. In addition, the report lists company-specific R&D pipelines of C. difficile vaccines and therapeutics. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Key Topics Covered - C. difficile Vaccines - C. difficile Antibodies - C. difficile Antibiotics - C. difficile targeting Microorganisms - C. difficile Anti-Infectives - Corporate C. difficile Vaccines & Therapeutics R&D Pipelines Companies Mentioned - Actelion - AIMM Therapeutics - AmpliPhi Biosciences - Astellas Pharma - AstraZeneca (MedImmune) - Aviex Technologies - Biota Pharmaceuticals - Crestone - Cubist Pharmaceuticals - DaVolterra - Immuron - Merck - Novacta Therapeutics - Novartis - Pfizer - Prokarium - Rebiotix - Sanofi Pasteur - Seres Health - Shire (ViroPharma) - Stellar Biotechnologies - Summit - Synthetic Biologics - Valneva - VaxInnate - Venenum Biodesign For more information visit http://www.researchandmarkets.com/research/kkvg3x/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Biota Pharmaceuticals Reports Second Quarter 2013 Financial Results and Recent Corporate Developments
GlobeNewswire - Mon Feb 10, 6:00AM CST
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company"
today announced its financial results for the three month and six month periods ended December 31, 2013, and provided an update on recent corporate developments. Biota Pharmaceuticals to Host Conference Call to Report Second Quarter Financial Results on February 10, 2014
GlobeNewswire - Mon Feb 03, 8:00AM CST
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company"
announced today that management will host a conference call on Monday, February 10, 2014 at 9:00a.m EST to review the Company's second quarter financial results and provide an update on recent corporate developments. The Company will issue a press release summarizing its financial results on the same day, prior to the conference call. Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 03, 2:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/fg3mhf/hospital_acquired) has announced the addition of the "Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2013" report to their offering. 'Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hospital Acquired Pneumonia (HAP), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hospital Acquired Pneumonia (HAP). Scope - A snapshot of the global therapeutic scenario for Hospital Acquired Pneumonia (HAP). - A review of the Hospital Acquired Pneumonia (HAP) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hospital Acquired Pneumonia (HAP) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned AstraZeneca PLC Cubist Pharmaceuticals, Inc. Basilea Pharmaceutica AG Aridis Pharmaceuticals LLC Tetraphase Pharmaceuticals Inc. Meiji Seika Pharma Co., Ltd. Biota Pharmaceuticals, Inc. Adenium Biotech ApS Melinta Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/fg...l_acquired About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Enterococcus Faecium Infections - Pipeline Review, H2 2013 Research Report
M2 - Wed Jan 29, 2:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/zdqfb5/enterococcus) has announced the addition of the "Enterococcus Faecium Infections - Pipeline Review, H2 2013" report to their offering. 'Enterococcus Faecium Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Enterococcus Faecium Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Enterococcus Faecium Infections. Scope - A snapshot of the global therapeutic scenario for Enterococcus Faecium Infections. - A review of the Enterococcus Faecium Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Enterococcus Faecium Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Dainippon Sumitomo Pharma Co., Ltd. Aquapharm Biodiscovery Limited Cellceutix Corporation Omnia Molecular Ltd. Biota Pharmaceuticals, Inc. Abgentis Limited Melinta Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/zd...terococcus About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Biota Announces Full Exercise of Over-Allotment Option
GlobeNewswire - Tue Jan 14, 6:00AM CST
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company"
today announced that Guggenheim Securities, LLC has exercised its option to purchase an additional 872,085 common shares to cover over-allotments in connection with the Company's public offering of its common shares. The full exercise of the over-allotment option increases the net proceeds to the company, after underwriting discounts and commissions and estimated offering expenses, from approximately $23.3 million to approximately $26.9 million. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes. Biota Prices $25 Million Public Offering
GlobeNewswire - Fri Jan 10, 7:30AM CST
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company"
today announced that it has priced a public offering of 5,813,900 shares of its common stock at a purchase price of $4.30 per share for an aggregate offering amount of approximately $25 million. The net proceeds to Biota from the sale of the shares, after underwriting discounts and commissions and other offering expenses, are expected to be approximately $23.3 million. Biota has granted the underwriters a 30-day option to purchase up to 872,085 additional shares to cover over-allotments, if any. The offering is expected to close on January 15, 2014, subject to customary closing conditions. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes. Biota Pharmaceuticals Inc proposes public offering of common shares
M2 - Fri Jan 10, 4:47AM CST
Biopharmaceutical company Biota Pharmaceuticals Inc (NasdaqGS:BOTA) said on Thursday that it plans to start a public offering of its common stock.
Biota Announces Proposed Public Offering
GlobeNewswire - Thu Jan 09, 3:01PM CST
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company"
today announced its intention, subject to market and other conditions, to commence a public offering of its common stock. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes. Biota Pharmaceuticals Inc announces approval of Laninamivir Octanoate in Japan for the prevention of influenza
M2 - Mon Dec 23, 6:33AM CST
Biopharmaceutical company Biota Pharmaceuticals Inc (NasdaqGS:BOTA) revealed on Friday the receipt of regulatory approval in Japan to manufacture and market Inavir Dry Powder Inhaler 20mg for the prevention of influenza A and B.
Biota Reports That Laninamivir Octanoate is Approved for the Prevention of Influenza in Japan
GlobeNewswire - Fri Dec 20, 3:49PM CST
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company"
today reported that Daiichi Sankyo Company, Limited ("Daiichi Sankyo" has been granted regulatory approval in Japan to manufacture and market Inavir Dry Powder Inhaler 20mg (generic name laninamivir octanoate) for the prevention of influenza A and B. Inavir was successfully developed and launched by Daiichi Sankyo in Japan for treatment of influenza A and B viruses in October, 2010. Biota is developing laninamivir octanoate outside of Japan for the treatment of influenza, and is currently conducting a large, multi-national Phase 2 trial of laninamivir octanoate in adults infected with influenza. In 2003, the Company and Daiichi Sankyo entered into a collaboration and license agreement to develop long-acting neuraminidase inhibitors, including laninamivir octanoate, and in March 2009, the parties entered into a commercialization agreement, pursuant to which Daiichi Sankyo obtained exclusive marketing rights to laninamivir octanoate in Japan. Biota reports launch of Phase 2 IGLOO trial of LANI in the Northern Hemisphere for treating influenza
M2 - Thu Dec 05, 10:27AM CST
Biopharmaceutical company Biota Pharmaceuticals Inc (NasdaqGS:BOTA) reported on Thursday the start of dosing of patients under its ongoing Phase 2, randomised, double blind, placebo controlled, parallel arm clinical trial of laninamivir octanoate (LANI) in the Northern Hemisphere.
Biota Initiates Dosing in Phase 2 IGLOO Trial of LANI in the Northern Hemisphere
GlobeNewswire - Thu Dec 05, 7:03AM CST
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company"
today announced that it has commenced dosing patients in the Northern Hemisphere portion of its ongoing Phase 2, randomized, double blind, placebo controlled, parallel arm clinical trial of laninamivir octanoate (LANI). The trial, referred to as "IGLOO", compares the safety and efficacy of 40 mg and 80 mg of LANI with placebo, all delivered by a TwinCaps inhaler in adults with presumed influenza A or B infection. The trial was initiated in the Southern Hemisphere in June and is now continuing in multiple countries in the Northern Hemisphere. The Company's goal is to complete enrollment in the IGLOO trial by the end of the influenza season in the Northern Hemisphere and have top-line data available in mid-2014. IGLOO is being conducted in connection with the Company's contract with the U.S. Office of Biomedical Advanced Research and Development Authority ("BARDA" . Further details regarding the design of IGLOO are available at www.clinicaltrials.gov. Biota Initiates Additional Clinical Trials of Laninamivir Octanoate
GlobeNewswire - Tue Nov 19, 6:00AM CST
Biota Pharmaceuticals Inc. ("Biota"
(Nasdaq:BOTA) announced today that it has commenced dosing in two Phase 1 clinical trials of laninamivir octanoate ("LANI" , its long-acting neuraminidase inhibitor being developed for the treatment of influenza. Novartis Reports Positive Results for Avian Flu Vaccine
Leo Sun, The Motley Fool - Motley Fool - Thu Nov 14, 2:18PM CST
Novartis today announced positive clinical trial results for its vaccine for the H7N9 avian flu, marking the first major step made by a large pharmaceutical company in treating the virus. There have been 135 confirmed H7N9 cases of and...
Biota Pharmaceuticals Reports First Quarter Financial Results
GlobeNewswire - Thu Nov 07, 6:00AM CST
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company"
today announced its financial results for the three month period ended September 30, 2013. Biota Pharmaceuticals to Host Conference Call to Report First Quarter Financial Results on November 7, 2013
GlobeNewswire - Mon Oct 28, 8:00AM CDT
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company"
announced today that management will host a conference call on Thursday, November 7, 2013 at 9:00a.m. EST to review the Company's first quarter financial results and provide an update on recent corporate developments. The Company will issue a press release summarizing its financial results on the same day, prior to the conference call. Biota Pharmaceuticals Reports Fourth Quarter and Fiscal Year-End Financial Results
GlobeNewswire - Wed Sep 18, 6:00AM CDT
Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company"
today announced financial results for its fourth quarter and fiscal year ended June 30, 2013, and provided an update on recent corporate developments and its financial guidance. 
